

May 27, 2023

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b>  <b>Company Code No. AUROPHARMA</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b>  <b>Company Code No. 524804</b>
--	--

Dear Sir,

**Sub: Press Release on Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2023.**

We enclose a copy of the Press Release on Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2023.

Please take the information on record.

Yours faithfully,  
**For AUROBINDO PHARMA LIMITED**

**B. Adi Reddy**  
**Company Secretary**

Enclosures: as above.

**AUROBINDO PHARMA LIMITED**  
[www.aurobindo.com](http://www.aurobindo.com)

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500038 T.S., INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833  
Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)

**Press Release**

Investor Relations | Corporate Communications  
Phone: 040-66725041 / 66725000  
Email: [ir@aurobindo.com](mailto:ir@aurobindo.com)

Hyderabad, India, May 27, 2023: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo") today announced its consolidated financial results for the quarter and year ended March 31, 2023.

**Aurobindo Pharma Ltd. Q4FY23 and FY23 Consolidated Financial Results**

Amount (INR Cr)	Q4FY23	Q4FY22	% Change YoY	Q3FY23	% Change QoQ	FY23	FY22	% Change YoY
Revenue from operations	6,473.0	5,809.4	11.4%	6,407.1	1.0%	24,855.4	23,455.5	6.0%
EBITDA before Forex and Other Income	1,002.2	974.4	2.9%	954.4	5.0%	3,758.2	4,386.8	-14.3%
EBITDA margin (%)	15.5%	16.8%	-	14.9%	-	15.1%	18.7%	-
EBITDA before R&D	1,412.9	1,405.4	0.5%	1,369.6	3.2%	5,169.7	5,967.8	-13.4%
EBITDA margin before R&D (%)	21.8%	24.2%	-	21.4%	-	20.8%	25.4%	-
PBT before JV, Forex, and Exceptional items	713.3	740.8	-3.7%	668.6	6.7%	2,663.7	3,462.0	-23.1%
Net Profit after Share of Profit/Loss of JV and before minority interest	505.9	576.1	-12.2%	491.0	3.0%	1,927.7	2,647.1	-27.2%

**Key highlights of Q4 FY23**

- Revenue from Operations at INR 6,473 Cr increased by 11.4% YoY
- US formulations revenue increased by 11.6% YoY to INR 3,045 Cr
- Europe formulation revenue stood at INR 1,660 Cr, with an increase of 7.7% YoY
- Growth Markets revenue grew by 51.2% YoY to INR 592 Cr
- ARV revenue stood at INR 159 Cr
- API revenue grew by 11.4% YoY to INR 1,017 Cr
- EBITDA before Forex and Other income stood at INR 1,002 Cr; EBITDA margin for the quarter was 15.5%. Similar to the previous quarter, this quarter saw a substantial investment in R&D. EBITDA before R&D stood at Rs. 1,413 Cr and EBITDA margin at 21.8%
- Research & Development (R&D) spend at INR 410.7 Cr, 6.3% of revenues
- Received final approval for 26 ANDAs including 4 injectable products from the USFDA
- Net Profit stood at INR 506 Cr as against INR 491 Cr in the previous quarter
- Basic & Diluted EPS is INR 8.64 per share

**Commenting on the Company's performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said:** "We saw decent performance in the current quarter, on the back of stable demand and pricing environment across our portfolio and geographies. We remain committed to executing our growth strategies, continuing new launches, and focusing on operational efficiencies."



## Operational Performance (Consolidated)

Amount (INR Cr)	Q4FY23	Q4FY22	% Change YoY	Q3FY23	% Change QoQ	FY23	FY22	% Change YoY
<b>Formulations</b>								
USA	3,045	2,728	11.6%	3,001	1.4%	11,654	11,122	4.8%
Europe	1,660	1,541	7.7%	1,701	-2.4%	6,426	6,480	-0.8%
Growth Markets*	592	391	51.2%	499	18.6%	1,973	1,504	31.2%
ARV	159	236	-32.5%	251	-36.6%	954	833	14.6%
<b>Total Formulations</b>	<b>5,456</b>	<b>4,896</b>	<b>11.4%</b>	<b>5,453</b>	<b>0.1%</b>	<b>21,007</b>	<b>19,939</b>	<b>5.4%</b>
<b>Active Pharmaceutical Ingredients (API)</b>								
Betalactam	638	594	7.3%	623	2.4%	2,448	2,083	17.6%
Non Betalactam	380	319	19.1%	332	14.5%	1,400	1,433	-2.3%
<b>Total API</b>	<b>1,017</b>	<b>913</b>	<b>11.4%</b>	<b>955</b>	<b>6.6%</b>	<b>3,848</b>	<b>3,516</b>	<b>9.4%</b>
<b>Consolidated Gross Sales (incl. service income)</b>	<b>6,473</b>	<b>5,809</b>	<b>11.4%</b>	<b>6,407</b>	<b>1.0%</b>	<b>24,855</b>	<b>23,455</b>	<b>6.0%</b>
Dossier Income	-	0.4	-	-	-	-	1	-
<b>Revenue from operations</b>	<b>6,473</b>	<b>5,809</b>	<b>11.4%</b>	<b>6,407</b>	<b>1.0%</b>	<b>24,855</b>	<b>23,456</b>	<b>6.0%</b>



\*includes domestic formulation sales of Rs. 52.9 Crs in Q4 FY23

## Q4 FY23: Consolidated revenue breakup - Geography & Segment wise

### FY23



## Q4 FY23



## Formulations

For the quarter, Formulation revenue increased by 11.4% YoY to INR 5,456 Crs.

### US Formulations

- In Q4 FY23, US revenue increased by 11.6% YoY to INR 3,045 Crs and accounted for 47.0% of consolidated revenues
- Filed 12 ANDAs including 3 Injectables with USFDA in Q4 FY23
- Received final approval for 26 ANDAs including 4 injectable products in Q4 FY23
- As on 31st March 2023, on a cumulative basis, the company has filed 774 ANDAs with USFDA and received final approval for 565 ANDAs and 34 tentative\* approvals
- The company has launched 10 products during the quarter including 4 Injectable products.

*\*Tentative approvals include 8 ANDAs approved under PEPFAR*

### Europe Formulations

- Europe revenue in Q4 FY23 increased by 7.7% YoY at INR 1,660 Crs. Europe Formulations accounted for 25.6% of consolidated revenues. In Euro terms, Europe revenue increased by 3.0% YoY to EUR 188 million

### ARV Formulations

- ARV business revenue for Q4 FY23 stood at INR 159 Crs., accounting for 2.5% of total revenues.

### Growth Markets Formulations

- Revenue from Growth Markets formulations in Q4 FY23 posted a growth of 51.2% YoY and 18.6% QoQ to INR 592 Crs and accounted for 9.1% of revenue. Domestic formulation sales in Q4 FY23 was Rs. 52.9 Crs.

### Active Pharmaceutical Ingredients (API)

- In Q4 FY23, API business stood at INR 1,017 Crs., increased by 11.4% YoY and 6.6% QoQ and contributed 15.7% to the consolidated revenues
- The company filed 3 DMFs with USFDA during the quarter.

## Global Regulatory Filings

Details	Q4FY23	Cumulative Filings as on 31st March 2022
ANDAs* (including filings from Aurobindo USA)	12	774
DMFs (including filings from Eugia and Auro Peptides)	3	276
Formulations Dossiers in other key advanced markets (incl. multiple registrations in Europe, South Africa and Canada)	47	4,359
API DMF/COS filings in other key regulated markets (incl. multiple registrations)	29	3,994

\*includes NDA

## Final USFDA Approvals Received in Q4 FY23

#	Product	Therapy
1	Azacitidine for Injection, 100 mg Single-Dose Vial	Antineoplastic
2	Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg and 200 mg	Central Nervous System Drugs
3	Brivaracetam Tablets, 50 mg and 100 mg	Central Nervous System Drugs
4	Levomilnacipran Extended-Release Capsules, 20 mg, 40 mg, 80 mg, and 120 mg	Central Nervous System Drugs
5	Norethindrone Tablets USP, 0.35 mg	Oral Contraceptive
6	Diclofenac Sodium Topical Solution USP, 2% w/w	Anti inflammatory
7	Linacotide Capsules, 145 mcg and 290 mcg	Gastrointestinal Agent
8	Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, and 425 mg	Cardiovascular
9	Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets USP, 5 mg/120 mg (OTC)	Anti Histamine
10	Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 100 mg/150 mg, 133 mg/200 mg, and 167 mg/250 mg	Anti-Retroviral
11	Ibuprofen and Pseudoephedrine Hydrochloride Tablets USP, 200 mg/30 mg (OTC)	Pain management
12	Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg	Central Nervous System Drugs
13	Emtricitabine Capsules, 200 mg	Anti-Retroviral
14	Prednisolone Tablets USP, 5 mg	Steroid
15	Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg	Central Nervous System Drugs
16	Loratadine Capsules USP, 10 mg (OTC)	Anti Histamine
17	Lansoprazole Delayed-Release Orally Disintegrating Tablets, 15 mg and 30 mg.	Gastrointestinal
18	Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg	Central Nervous System
19	Nitrofurantoin Capsules USP (Monohydrate/Macrocrystals), 100 mg	Anti-infective
20	Mesalamine Extended-Release Capsules USP, 0.375 g	Anti inflammatory
21	Prazosin Hydrochloride Capsules USP, 1 mg, 2 mg and 5 mg	Cardiovascular
22	Voriconazole for Injection, 200 mg/Vial (Single-Dose Vial)	Antifungal Antibiotic
23	Hydralazine Hydrochloride Injection USP, 20 mg/mL Single-Dose Vials	Cardiovascular
24	Lenalidomide Capsules, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg	Immunomodulatory agent
25	Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%	Ophthalmic
26	Diltiazem Hydrochloride Injection, 25 mg/5 mL (5 mg/mL), 50 mg/10 mL (5 mg/mL), and 125 mg/25 mL (5 mg/mL), Single-Dose Vials	Cardiovascular

## Q4 FY23 Earnings Call Details

The company will host earnings call at **8.30 AM IST on 29<sup>th</sup> May 2023**, to discuss the performance and answer any questions from participants.

**To join the call through Zoom:**

**Please pre-register by clicking here:** <https://bit.ly/45fnGq7>

## About Aurobindo Pharma Limited

Aurobindo Pharma Limited ([www.aurobindo.com](http://www.aurobindo.com)), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) headquartered at Hyderabad, India, develops, manufactures, and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, EU, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up. The Company is marketing these products globally in over 150 countries.

## For Further Information, please contact:

Investor Relations | Corporate Communications

Phone: 040-66725401 / 66725000

Email: [ir@aurobindo.com](mailto:ir@aurobindo.com)